The $2.3 billion fine against Pfizer announced last week 1 is expected to lead to far greater oversight of the way prescription drugs are marketed in the US. The record-breaking fine was a punishment for the off-label promotion of four products: the anti-inflammatory Bextra (valdecoxib), the antipsychotic Geodon (ziprasidone HCl), the antibiotic Zyvox (linezolid) and the anti-epileptic Lyrica (pregabalin)...
Please login to read the full article.
